Research Articles

Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease

A double-blind, randomized, clinical field trial was designed to test the efficacy and tolerance of a specific drug treatment in children in the indeterminate phase of infection by Trypanosoma cruzi. Children were treated with benznidazole at a dose of 5 mg/kg/day for 60 days or placebo and followed-up for 48 months. The treated children showed a significant decrease in geometric mean titers of antibodies against T. cruzi measured by indirect hemagglutination, indirect immunofluorescence, and ELISA. After a four year follow-up, 62% of the benznidazole-treated children and no placebo-treated child were seronegative for T. cruzi when tested by an ELISA using a T. cruzi flagellar calcium-binding protein (F29). Xenodiagnosis carried out after 48 months of follow-up was positive in 4.7% of the benznidazole-treated children and in 51.2% of the placebo-treated children. These results show the tolerance to and efficacy of benznidazole against T. cruzi in seropositive children six to 12 years of age. We used an early serologic marker of cure after treatment, consisting of a recombinant antigen implemented in a rapid, conventional serologic procedure.

This article has been cited by other articles:

				P. Roddy, J. Goiri, L. Flevaud, P. P. Palma, S. Morote, N. Lima, L. Villa, F. Torrico, and P. Albajar-Vinas Field Evaluation of a Rapid Immunochromatographic Assay for Detection of Trypanosoma cruzi Infection by Use of Whole Blood J. Clin. Microbiol., June 1, 2008; 46(6): 2022 - 2027. [Abstract] [Full Text] [PDF]

				C. Bern, S. P. Montgomery, B. L. Herwaldt, A. Rassi Jr, J. A. Marin-Neto, R. O. Dantas, J. H. Maguire, H. Acquatella, C. Morillo, L. V. Kirchhoff, et al. Evaluation and Treatment of Chagas Disease in the United States: A Systematic Review JAMA, November 14, 2007; 298(18): 2171 - 2181. [Abstract] [Full Text] [PDF]

				P. S. Doyle, Y. M. Zhou, J. C. Engel, and J. H. McKerrow A Cysteine Protease Inhibitor Cures Chagas' Disease in an Immunodeficient-Mouse Model of Infection Antimicrob. Agents Chemother., November 1, 2007; 51(11): 3932 - 3939. [Abstract] [Full Text] [PDF]

				A R L Teixeira, N Nitz, M C Guimaro, C Gomes, and C A Santos-Buch Chagas disease Postgrad. Med. J., December 1, 2006; 82(974): 788 - 798. [Abstract] [Full Text] [PDF]

				M. FLORES-CHAVEZ, M.-F. BOSSENO, B. BASTRENTA, J.-L. A. DALENZ, M. HONTEBEYRIE, S. REVOLLO, and S. F. BRENIERE POLYMERASE CHAIN REACTION DETECTION AND SEROLOGIC FOLLOW-UP AFTER TREATMENT WITH BENZNIDAZOLE IN BOLIVIAN CHILDREN INFECTED WITH A NATURAL MIXTURE OF TRYPANOSOMA CRUZI I AND II. Am J Trop Med Hyg, September 1, 2006; 75(3): 497 - 501. [Abstract] [Full Text] [PDF]

				R. Viotti, C. Vigliano, B. Lococo, G. Bertocchi, M. Petti, M. G. Alvarez, M. Postan, and A. Armenti Long-Term Cardiac Outcomes of Treating Chronic Chagas Disease with Benznidazole versus No Treatment: A Nonrandomized Trial Ann Intern Med, May 16, 2006; 144(10): 724 - 734. [Abstract] [Full Text] [PDF]

				I. S. Marcipar, C. Roodveldt, G. Corradi, M. L. Cabeza, M. E. F. Brito, L. M. F. Winter, A. J. Marcipar, and A. M. Silber Use of Full-Length Recombinant Calflagin and Its C Fragment for Improvement of Diagnosis of Trypanosoma cruzi Infection J. Clin. Microbiol., November 1, 2005; 43(11): 5498 - 5503. [Abstract] [Full Text] [PDF]

				O. S. Negrette, M. C. Mora, and M. A. Basombrio High Prevalence of Congenital Trypanosoma cruzi Infection and Family Clustering in Salta, Argentina Pediatrics, June 1, 2005; 115(6): e668 - e672. [Abstract] [Full Text] [PDF]

				M. Corrales, R. Cardozo, M. A. Segura, J. A. Urbina, and M. A. Basombrio Comparative Efficacies of TAK-187, a Long-Lasting Ergosterol Biosynthesis Inhibitor, and Benznidazole in Preventing Cardiac Damage in a Murine Model of Chagas' Disease Antimicrob. Agents Chemother., April 1, 2005; 49(4): 1556 - 1560. [Abstract] [Full Text] [PDF]

				A. L. S. S. ANDRADE, C. M. T. MARTELLI, R. M. OLIVEIRA, S. A. SILVA, A. I. S. AIRES, L. M. T. SOUSSUMI, D. T. COVAS, L. S. SILVA, J. G. ANDRADE, L. R. TRAVASSOS, et al. SHORT REPORT: BENZNIDAZOLE EFFICACY AMONG TRYPANOSOMA CRUZI-INFECTED ADOLESCENTS AFTER A SIX-YEAR FOLLOW-UP Am J Trop Med Hyg, November 1, 2004; 71(5): 594 - 597. [Abstract] [Full Text] [PDF]

				W. S. F. Meira, L. M. C. Galvao, E. D. Gontijo, G. L. L. Machado-Coelho, K. A. Norris, and E. Chiari Use of the Trypanosoma cruzi Recombinant Complement Regulatory Protein To Evaluate Therapeutic Efficacy following Treatment of Chronic Chagasic Patients J. Clin. Microbiol., February 1, 2004; 42(2): 707 - 712. [Abstract] [Full Text] [PDF]

				L. M. C. Galvao, E. Chiari, A. M. Macedo, A. O. Luquetti, S. A. Silva, and A. L. S. S. Andrade PCR Assay for Monitoring Trypanosoma cruzi Parasitemia in Childhood after Specific Chemotherapy J. Clin. Microbiol., November 1, 2003; 41(11): 5066 - 5070. [Abstract] [Full Text] [PDF]

				A. G. Schijman, J. Altcheh, J. M. Burgos, M. Biancardi, M. Bisio, M. J. Levin, and H. Freilij Aetiological treatment of congenital Chagas' disease diagnosed and monitored by the polymerase chain reaction J. Antimicrob. Chemother., September 1, 2003; 52(3): 441 - 449. [Abstract] [Full Text] [PDF]

				A. Solari, S. Ortiz, A. Soto, C. Arancibia, R. Campillay, M. Contreras, P. Salinas, A. Rojas, and H. Schenone Treatment of Trypanosoma cruzi-infected children with nifurtimox: a 3 year follow-up by PCR J. Antimicrob. Chemother., October 1, 2001; 48(4): 515 - 519. [Abstract] [Full Text] [PDF]

				J. C. Villar Commentary: Control of Chagas' disease: let's put people before vectors Int. J. Epidemiol., August 1, 2001; 30(4): 894 - 895. [Full Text] [PDF]

				J. Engel, C. Garcia, I Hsieh, P. Doyle, and J. McKerrow Upregulation of the secretory pathway in cysteine protease inhibitor-resistant Trypanosoma cruzi J. Cell Sci., January 4, 2000; 113(8): 1345 - 1354. [Abstract] [PDF]